Phase IIb programme of IPP 204106 in patients with metastatic melanoma, glioblastoma, hormone-resistant prostate cancer or pancreatic cancer

Trial Profile

Phase IIb programme of IPP 204106 in patients with metastatic melanoma, glioblastoma, hormone-resistant prostate cancer or pancreatic cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2013

At a glance

  • Drugs IPP 204106 (Primary)
  • Indications Glioblastoma; Malignant melanoma; Pancreatic cancer; Prostate cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 13 Aug 2013 This trial is progressing according to protocol, according to an ImmuPharma media release.
    • 06 Dec 2010 New trial record
    • 19 Nov 2010 ImmuPharma plans to file a US IND for IPP 204106 in the next few months, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top